Company intelligence / Profile preview
PLx Pharma Inc.
Sparta, New Jersey, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
PLx Pharma developed the patent-protected PLxGuard™ drug delivery platform designed to release active pharmaceutical ingredients in the duodenum rather than the stomach, aiming to improve absorption and reduce gastrointestinal side effects. Their lead product was a GI-safer aspirin formulation intended for cardiovascular disease prevention. The company also had a clinical-stage ibuprofen program. Despite promising technology and clinical validation, the company entered bankruptcy after raising over $40 million in funding.
- Therapeutic areas
- CardiovascularRheumatology
- Modalities
- Small molecules (focus on oral NSAIDs such as aspirin and ibuprofen)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on PLx Pharma Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLx Pharma Inc..